ABSTRACT
RESUMO Objetivo: Caracterizar a lesão miocárdica e as complicações cardiovasculares e seus preditores em pacientes graves e críticos com COVID-19 admitidos à unidade de terapia intensiva. Métodos: Este foi um estudo de coorte observacional em pacientes graves e críticos com COVID-19 admitidos à unidade de terapia intensiva. A lesão miocárdica foi definida como níveis sanguíneos de troponina cardíaca acima do limite de referência superior ao percentil 99. Os eventos cardiovasculares considerados foram combinação de trombose venosa profunda, embolia pulmonar, acidente vascular cerebral, infarto do miocárdio, isquemia aguda de membros, isquemia mesentérica, insuficiência cardíaca e arritmia cardíaca. Regressão logística univariada e multivariada ou modelos de risco proporcional de Cox foram utilizados para determinar os preditores de lesão miocárdica. Resultados: Foram admitidos à unidade de terapia intensiva 567 pacientes graves e críticos com COVID-19, dos quais 273 (48,1%) apresentavam lesão miocárdica. Dos 374 pacientes críticos com COVID-19, 86,1% tinham lesão miocárdica, além de apresentarem mais disfunção orgânica e maior mortalidade aos 28 dias (56,6% versus 27,1%; p < 0,001). Foram preditores de lesão miocárdica idade avançada, hipertensão arterial e uso de imunomoduladores. Complicações cardiovasculares ocorreram em 19,9% dos pacientes graves e críticos com COVID-19 admitidos à unidade de terapia intensiva, e a maioria dos eventos deu-se em pacientes com lesão miocárdica (28,2% versus 12,2%; p < 0,001). A ocorrência de evento cardiovascular precoce durante internação em unidade de terapia intensiva estava associada à maior mortalidade aos 28 dias em comparação com eventos tardios ou inexistentes (57,1% versus 34,0% versus 41,8%; p = 0,01). Conclusão: Pacientes com formas graves e críticas de COVID-19 admitidos à unidade de terapia intensiva foram comumente diagnosticados com lesão miocárdica e complicações cardiovasculares, e ambas estavam associadas à maior mortalidade nesses pacientes.
ABSTRACT Objective: To characterize myocardial injury and cardiovascular complications and their predictors in severe and critical COVID-19 patients admitted to the intensive care unit. Methods: This was an observational cohort study of severe and critical COVID-19 patients admitted to the intensive care unit. Myocardial injury was defined as blood levels of cardiac troponin above the 99th percentile upper reference limit. Cardiovascular events considered were the composite of deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, acute limb ischemia, mesenteric ischemia, heart failure and arrhythmia. Univariate and multivariate logistic regression or Cox proportional hazard models were used to determine predictors of myocardial injury. Results: Of 567 patients with severe and critical COVID-19 admitted to the intensive care unit, 273 (48.1%) had myocardial injury. Of the 374 patients with critical COVID-19, 86.1% had myocardial injury, and also showed more organ dysfunction and higher 28-day mortality (56.6% versus 27.1%, p < 0.001). Advanced age, arterial hypertension and immune modulator use were predictors of myocardial injury. Cardiovascular complications occurred in 19.9% of patients with severe and critical COVID-19 admitted to the intensive care unit, with most events occurring in patients with myocardial injury (28.2% versus 12.2%, p < 0.001). The occurrence of an early cardiovascular event during intensive care unit stay was associated with higher 28-day mortality compared with late or no events (57.1% versus 34% versus 41.8%, p = 0.01). Conclusion: Myocardial injury and cardiovascular complications were commonly found in patients with severe and critical forms of COVID-19 admitted to the intensive care unit, and both were associated with increased mortality in these patients.
ABSTRACT
INTRODUCCION: El Síndrome Inflamatorio Pediátrico Multisistémico (PIMS) ha emergido como una nueva enfermedad en niños, secundaria a infección por SARSCoV-2. Se caracteriza por presentar compromiso multiorgánico con parámetros inflamatorios elevados y manifestaciones clínicas graves, siendo el corazón el órgano más severamente comprometido. OBJETIVO: Describir las características clínicas y de laboratorio de 23 pacientes con diagnóstico de PIMS con compromiso cardiovascular hospitalizados en un centro único. MÉTODO: Se efectuó un estudio retrospectivo analizando los hallazgos clínicos y de laboratorio junto a las manifestaciones cardiovasculares que presentaron estos pacientes. RESULTADOS: 23/29 pacientes con PIMS (78%) presentaron manifestaciones digestivas y mucocutáneas. Las manifestaciones cardiovasculares fueron: Síndrome Kawasaki y "Kawasaki like" sin compromiso coronario en 15/23 (65%) y con compromiso coronario en 3 (13%). Shock en 9 pacientes (39%), injuria miocárdica- miocarditis en 8 (35%) y derrame pericárdico en 13 (56%). Trastornos del ritmo cardíaco se observaron en 6 pacientes (26%). La terapia más utilizada fue inmunoglobulina y corticoides. 18 /23 requirieron manejo en unidades de intermedio y/o intensivo. Un 70% de los pacientes se recuperó del compromiso cardiovascular antes del alta. CONCLUSIÓN: El compromiso cardiovascular en PIMS es la complicación más frecuente de esta enfermedad, que se acompaña de manifestaciones inmunológicas y hematológicas graves lo que hace necesario un tratamiento multidisciplinario para un mejor manejo de estos pacientes.
INTRODUCTION: Pediatric Multisystemic Inflammatory Syndrome (PIMS) has emerged as a new disease in children, secondary to SARSCoV-2 infection. It is characterized by multi-organ involvement with elevated inflammatory parameters and severe clinical manifestations, the heart being the organ most severely involved. OBJETIVE: to describe the clinical and laboratory characteristics of 23 patients diagnosed with PIMS with cardiovascular involvement hospitalized in a single center. METHOD: We conducted a retrospective study in which we analyzed the clinical and laboratory findings along with the cardiovascular manifestations presented by these patients. Results: 23/29 patients with PIMS and cardiovascular involvement were selected, 78% had digestive and mucocutaneous manifestations. Cardiovascular manifestations consisted of KawasakiKawasaki like syndrome without coronary involvement in 15/23 (65%) and coronary involvement in 3 (13%). Nine patients developed shock (39%), 8 (35%) myocardial injury in and 13 (56%) pericardial effusion.. Heart rhythm disorders were observed in 6 patients (26%). The main therapy was immunoglobulin and corticosteroids. 18 /23 required management in intermediate and/or intensive care unit. 70% of patients recovered from cardiovascular involvement before discharge. CONCLUSION: Cardiovascular involvement in PIMS is the most frequent complication of this disease, but it is associated with severe immunological and hematological manifestations, which makes necessary a multidisciplinary treatment for a better management
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Cardiovascular Diseases/etiology , Cardiovascular Diseases/epidemiology , Systemic Inflammatory Response Syndrome/complications , COVID-19/complications , Coronary Aneurysm/etiology , Coronary Aneurysm/epidemiology , Echocardiography , Chile , Retrospective Studies , Age Distribution , SARS-CoV-2 , Heart Injuries/etiology , Heart Injuries/epidemiology , Hospitalization , Mucocutaneous Lymph Node Syndrome/etiology , Mucocutaneous Lymph Node Syndrome/epidemiologyABSTRACT
Desde la aparición de la pandemia por SARS-CoV-2, la población pediátrica ha sido menos afectada por la enfermedad tanto en frecuencia como en severidad. Sin embargo, desde abril de este año se han reportado casos de presentación y gravedad variables, caracterizados por fenómenos inflamato rios que afectan múltiples órganos, condición denominada Síndrome Inflamatorio Multisistémico Pediátrico (PIMS). La literatura describe frecuente compromiso cardíaco, hasta en un 80%. Este se caracteriza por injuria miocárdica con significativa elevación de biomarcadores: Troponinas séricas I/T, BNP o NT-ProBNP, unido a diversos grados de disfunción ventricular, pericarditis, valvulitis y arritmias. Además, se ha evidenciado la presencia de compromiso coronario el cual puede ocurrir hasta en un 23% de los casos, en un rango que va desde dilataciones hasta aneurismas. El seguimien to cardiológico hospitalizado y ambulatorio se ha sistematizado en base a los fenotipos clínicos de presentación: injuria miocárdica (miocarditis, valvulitis, pericarditis), shock (habitualmente de tipo "vasopléjico"), manifestaciones tipo Enfermedad de Kawasaki y aquellos casos PIMS que no cumplen con la clínica de los tres precedentes. Este último grupo es el que representa el mayor desafío en el cor to, mediano y seguimiento a largo plazo. Por esta razón se requiere un equipo multidisciplinario para su manejo. Considerando la alta frecuencia del compromiso cardíaco en el PIMS y la importancia de lograr un consenso en su manejo y seguimiento, se presentan estas recomendaciones según el estado actual del conocimiento de esta patología recientemente descrita.
Since the onset of the SARS-CoV-2 pandemic, the pediatric population has been less affected by the disease both in frequency and severity. However, since April cases of variable presentation and severity characterized by inflammatory phenomena that affect multiple organs have been reported, a condition called Multisystem Inflammatory Syndrome in Children (MIS-C). The literature has reported frequent cardiac involvement, up to 80%. This is characterized by myocardial injury with a significant increase of biomarkers such as serum troponins I and T, BNP, or NT-ProBNP coupled with varying degrees of ventricular dysfunction, pericarditis, valvulitis, and arrhythmias. Coronary compromise has also been described, which can occur in up to 23% of cases, and ranges from dila tations to aneurysms. Inpatient and outpatient cardiology follow-up has been systematized based on the clinical phenotypes such as myocardial injury (myocarditis, valvulitis, pericarditis), shock (usua lly vasoplegic), Kawasaki disease-type manifestations, and those MIS-C that do not comply with the clinic of the previous three. This last group represents the main challenge in the short-, medium- and long-term follow-up, therefore, it is necessary a multidisciplinary team for managing these patients. Considering the high frequency of cardiac compromise in MIS-C, and the importance of reaching a consensus regarding its management and follow-up, we present these recommendations according to the current state of knowledge regarding this recently described pathology.
Subject(s)
Humans , Child , Cardiovascular Diseases/virology , Systemic Inflammatory Response Syndrome/therapy , COVID-19/therapy , Patient Care Team/organization & administration , Shock/therapy , Shock/virology , Biomarkers/metabolism , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/therapy , Chile , Systemic Inflammatory Response Syndrome/diagnosis , Systemic Inflammatory Response Syndrome/physiopathology , COVID-19/diagnosis , COVID-19/physiopathology , Mucocutaneous Lymph Node Syndrome/therapy , Mucocutaneous Lymph Node Syndrome/virologyABSTRACT
El compromiso cardiovascular de los pacientes con COVID-19, especialmente en la subpoblación con factores de riesgo cardiovasculares, se asocia a la severidad de la enfermedad e inclusive a una mayor mortalidad en algunas series de casos. Los mecanismos fisiopatológicos descritos con mayor claridad son la injuria miocárdica directa y el proceso asociado a la inflamación sistémica.Las manifestaciones cardiovasculares son diversas e incluyen injuria miocárdica, miocarditis, miocardiopatías, insuficiencia cardíaca, síndromes coronarios agudos, arritmias, eventos tromboembólicos. Adicionalmente, debemos considerar los efectos adversos de los medicamentos utilizados para tratar la infección viral. (AU)
Cardiovascular compromise among COVID-19 patients, especially in the subpopulation with cardiovascular risk factors, is associated with severity of disease and a higher mortality in some case-series. The most clearly described pathophysiological mechanisms are direct myocardial injury and the process associated with systemic inflammation. Cardiovascular manifestations are diverse and include myocardial injury, myocarditis, cardiomyopathies, heart failure, acute coronary syndromes, arrhythmias, thromboembolic events. Moreover, we must consider the adverse effects of medications used to treat the viral infection. (AU)
Subject(s)
Humans , Arrhythmias, Cardiac , Cardiovascular Diseases , Coronavirus Infections , Severe acute respiratory syndrome-related coronavirus , CardiomyopathiesABSTRACT
Vascular surgery is considered high risk, due to the characteristics of patients and surgical procedures. Recently, the diagnosis of myocardial injury after non-cardiac surgery (MINS) was introduced to focus attention on the prognostic relevance of elevated ischemic troponin after non-cardiac surgery. In the study Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION), that included more than 15,000 patients who underwent non-cardiac surgery, MINS was independently associated with mortality 3 to 4 times greater than 30 days after surgery. Biccard et al published a study derived from the study VISION in which 502 patients underwent vascular surgery, resulting in significantly higher mortality (12.5% vs 1.5%, p < 0.001) in patients who developed MINS compared to those who did not develop MINS (OR 9.48, 95% CI, 3.46-25.96). The 2014 guidelines for preoperative cardiovascular evaluation of the American College of Cardiology/American Heart Association (ACC/AHA) do not recommend the postoperative surveillance of troponin in patients without symptoms or signs of myocardial ischemia, nor in patients at high risk of coronary disease (as patients undergoing vascular surgery). On the other hand, the 2017 guidelines of the Canadian Cardiovascular Society on Perioperative Cardiac Risk, evaluation and treatment for non-cardiac surgery patients, recommend obtaining daily measurements of troponin for 48 to 72 hours after of non-cardiac surgery, in patients with a baseline risk of more than 5% of cardiovascular death or acute non-fatal myocardial infarction at 30 days after surgery. MINS is a potentially useful marker of adverse postoperative outcomes and its detection could provide opportunities to improve clinical outcomes in affected patients.
La cirugía vascular es considerada de alto riesgo, debido a características propias de los pacientes y de los procedimientos quirúrgicos. Recientemente, se introdujo el diagnóstico de injuria miocárdica postcirugía no cardiaca (MINS) para centrar la atención en la relevancia pronóstica de la elevación de la troponina isquémica después de una cirugía no cardíaca. Dos grandes estudios han demostrado que la mortalidad es significativamente mayor en pacientes que desarrollaron MINS. Las guías 2014 de evaluación cardiovascular preoperatoria de American College of Cardiology/American Heart Association (ACC/AHA), no recomiendan la vigilancia postoperatoria de troponina en pacientes sin síntomas ni signos de isquemia miocárdica ni tampoco en pacientes con alto riesgo de infarto al miocardio (como pacientes sometidos a cirugía vascular). Sin embargo, las guías de sociedad cardiovascular canadiense (publicadas en 2017) sobre riesgo cardíaco perioperatorio, evaluación y tratamiento para pacientes de cirugía no cardíaca] recomiendan obtener mediciones diarias de troponina durante 48 a 72 horas después de cirugía no cardíaca, en pacientes con un riesgo basal superior al 5% de muerte cardiovascular o infarto agudo al miocardio no fatal a 30 días después de una cirugía. MINS se debe considerar como un marcador potencialmente útil de resultados postoperatorios adversos y su detección podría brindar oportunidades para mejorar los resultados clínicos en los pacientes afectados.
Subject(s)
Humans , Vascular Surgical Procedures/adverse effects , Heart Injuries/etiology , Heart Injuries/epidemiology , Prognosis , Biomarkers/blood , Risk Assessment , Troponin T/blood , Heart Injuries/diagnosisABSTRACT
La picadura de escorpión es una entidad que afecta al mundo entero y llega a ser la segunda causa más importante de envenenamiento de animales en todo el mundo. En Perú, se ha reportado al escorpión Hadruroides charcasus que se encuentra distribuido en los departamentos de la costa norte del país. La fisiopatología que explica la lesión miocárdica no está completamente establecida. Se reporta el caso de un paciente que presento picadura de escorpión y que curse con injuria miocárdica documentada. Se presenta la secuencia de hechos con sus resultados y una revisión de la literatura.
The scorpion sting is an entity that affects the whole world becoming the second largest animal poisoning worldwide. In Peru, it has been reported scorpion Hadruroides charcasus that is distributed in the departments of the north coast. Explaining the pathophysiology of myocardial injury is not fully established. We report a patient who presented scorpion sting and documented myocardial injury. We present the sequence of events with their results and a review of the literature.